08:43 AM EDT, 07/09/2025 (MT Newswires) -- Immuneering ( IMRX ) said Wednesday that the US Patent and Trademark Office has granted a composition of matter patent for its cancer drug candidate, atebimetinib.

The company said the patent titled 'MEK Inhibitors and Therapeutic Uses Thereof', covers the chemical composition of atebimetinib and is set to expire in August 2042, with potential for further extension depending on regulatory review timelines.

The drug developer said the decision follows clinical data from its ongoing phase 2a trial that showed that atebimetinib combined with chemotherapy significantly improved the probability of surviving six months compared with standard chemotherapy alone.

IMRX shares were up past 2% in Wednesday's premarket.